We are live on ! Find out more
PAP

Persistent Asset Partners Portfolio holdings

AUM $335M
1-Year Est. Return 275.57%
This Fund
S&P 500
This Quarter Est. Return
+35.4%
1 Year Est. Return
+275.57%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$268M
AUM Growth
+$45.6M
Cap. Flow
+$18.2M
Cap. Flow %
6.78%
Top 10 Hldgs %
33.7%
Holding
508
New
146
Increased
78
Reduced
73
Closed
186

Top Buys

Rank Stock Value
1
TSEM icon
Tower Semiconductor
TSEM
+$9.09M
2
LITE icon
Lumentum
LITE
+$8.24M
3
GLW icon
Corning
GLW
+$6.49M
4
INTC icon
Intel
INTC
+$5.94M
5
ALAB icon
Astera Labs
ALAB
+$4.77M

Top Sells

Rank Stock Value
1
CNC icon
Centene
CNC
+$9.07M
2
MOH icon
Molina Healthcare
MOH
+$8.9M
3
ELV icon
Elevance Health
ELV
+$8.08M
4
BTSG icon
BrightSpring Health Services
BTSG
+$3.52M
5
TERN
Terns Pharmaceuticals
TERN
+$2.78M

Sector Composition

Rank Sector Weight
1 Technology 44.62%
2 Healthcare 29.67%
3 Financials 9.04%
4 Consumer Discretionary 3.92%
5 Energy 3.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MSFT icon
426
Microsoft
MSFT
$3.69T
– –
-1,174
Closed -$568K
NAMS icon
427
NewAmsterdam Pharma
NAMS
$3.19B
– –
-3,948
Closed -$138K
NKE icon
428
Nike
NKE
$61.2B
– –
-2,100
Closed -$134K
NTLA icon
429
PUT
Intellia Therapeutics
NTLA
$1.66B
– –
-852
Closed -$118K
NTRA icon
430
Natera
NTRA
$44.8B
– –
-1,484
Closed -$340K
NVDA icon
431
CALL
NVIDIA
NVDA
$5.46T
– –
-9
Closed -$3.86K
NVST icon
432
Envista
NVST
$4.51B
– –
-4,264
Closed -$92.6K
OCUL icon
433
CALL
Ocular Therapeutix
OCUL
$2.22B
– –
-1,459
Closed -$311K
OCUL icon
434
Ocular Therapeutix
OCUL
$2.22B
– –
-23,984
Closed -$291K
OLMA icon
435
Olema Pharmaceuticals
OLMA
$920M
– –
-9,069
Closed -$202K
OSCR icon
436
Oscar Health
OSCR
$9.5B
– –
-18,976
Closed -$273K
PALL icon
437
CALL
abrdn Physical Palladium Shares ETF
PALL
$648M
– –
-60
Closed -$5.22K
PBYI icon
438
CALL
Puma Biotechnology
PBYI
$450M
– –
-91
Closed -$3.87K
PCRX icon
439
Pacira BioSciences
PCRX
$924M
– –
-12,962
Closed -$335K
PFSI icon
440
PennyMac Financial
PFSI
$4.13B
– –
-2,339
Closed -$308K
PLRX icon
441
Pliant Therapeutics
PLRX
$66.9M
– –
-38,831
Closed -$47.4K
PNTG icon
442
Pennant Group
PNTG
$1.35B
– –
-356
Closed -$10K
PRAX icon
443
PUT
Praxis Precision Medicines
PRAX
$10.3B
– –
-230
Closed -$15.6K
PRTA icon
444
Prothena Corp
PRTA
$466M
– –
-28,589
Closed -$273K
PTGX icon
445
Protagonist Therapeutics
PTGX
$9.8B
– –
-7,908
Closed -$691K
QQQ icon
446
PUT
Invesco QQQ Trust
QQQ
$487B
– –
-81
Closed -$6.88K
RARE icon
447
CALL
Ultragenyx Pharmaceutical
RARE
$2.6B
– –
-266
Closed -$1.13K
REGN icon
448
CALL
Regeneron Pharmaceuticals
REGN
$83B
– –
-13
Closed -$43.9K
RIGL icon
449
Rigel Pharmaceuticals
RIGL
$762M
– –
-7,995
Closed -$342K
RNAM
450
CALL
DELISTED
Avidity Biosciences
RNAM
– –
-839
Closed -$1.48M
16 17
18
19 20

Similar funds

SG
Standard General New York $336M AUM 16.52% 1-Year Est. Return
MA
MSA Advisors Santa Monica, California $333M AUM 8.79% 1-Year Est. Return
LA
LFL Advisers Evanston, Illinois $332M AUM 20.17% 1-Year Est. Return
RWM
Rench Wealth Management Denton, Texas $332M AUM 25.74% 1-Year Est. Return
BCM
Brightline Capital Management Miami, Florida $338M AUM 197.95% 1-Year Est. Return
JCA
Juniper Capital Advisors Houston, Texas $332M AUM 102.57% 1-Year Est. Return
EAM
EdenTree Asset Management London, United Kingdom $332M AUM 16.64% 1-Year Est. Return
CAC
Core Alternative Capital Peachtree Corners, Georgia $339M AUM 18.22% 1-Year Est. Return

Persistent Asset Partners's Q1 2026 Portfolio in Review

As of Q1 2026, Persistent Asset Partners held 508 positions worth $268M, up 20% from $223M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Persistent Asset Partners deployed $18.2M of net new capital in Q1 2026, opening 146 new positions and adding to 78 existing holdings. Its largest new stake was Tower Semiconductor: 67,608 shares worth $11.9M.

By sector, the portfolio is most concentrated in Technology at 45% of assets, up from 14% a quarter earlier, followed by Healthcare and Financials.

On the sell side, the largest reduction was Terns Pharmaceuticals, an estimated $2.78M trimmed.

  • Persistent Asset Partners's largest Q1 2026 buy was Tower Semiconductor: 67,608 shares worth $11.9M.
  • Persistent Asset Partners added most to Lumentum in Q1 2026, an estimated $8.24M increase.
  • Persistent Asset Partners's biggest Q1 2026 reduction was Terns Pharmaceuticals, cutting an estimated $2.78M.
  • Persistent Asset Partners fully exited Centene in Q1 2026, selling an estimated $9.07M.
  • Persistent Asset Partners's ten largest holdings make up 34% of its $268M portfolio in Q1 2026.
  • Persistent Asset Partners opened 146 new positions and closed 186 in Q1 2026.
  • Persistent Asset Partners's portfolio value rose 20% quarter-over-quarter to $268M.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.